Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US15745290Application Date: 2016-07-15
-
Publication No.: US10357484B2Publication Date: 2019-07-23
- Inventor: Akira Kaieda , Masaki Daini , Hiroshi Nara , Masato Yoshikawa , Naoki Ishii , Masashi Toyofuku , Kousuke Hidaka
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Hamre, Schumann, Mueller & Larson, P.C.
- Priority: JP2015-143353 20150717
- International Application: PCT/JP2016/070936 WO 20160715
- International Announcement: WO2017/014170 WO 20170126
- Main IPC: A61P25/28
- IPC: A61P25/28 ; A61K31/427 ; A61K31/437 ; A61K31/444 ; C07D413/04 ; C07D413/14 ; C07D417/14 ; C07D471/04 ; A61K31/4035 ; A61K31/4245 ; A61K31/4439

Abstract:
The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
Public/Granted literature
- US20190008836A1 HETEROCYCLIC COMPOUND Public/Granted day:2019-01-10
Information query